StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTIQ) stock

KPTIQOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
Share price
Not available yet

Price, market cap and P/E appear here once daily prices are connected.

Karyopharm Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Karyopharm Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$65.35M. For fiscal 2025 it was -$75.37M. The highest annual figure on record is -$8.55M in fiscal 2011.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$75.37M–
FY2024Dec 31, 2024-$127.49M–
FY2023Dec 31, 2023-$92.72M–
FY2022Dec 31, 2022-$149.55M–
FY2021Dec 31, 2021-$107.12M–
FY2020Dec 31, 2020-$160.23M–
FY2019Dec 31, 2019-$190.82M–
FY2018Dec 31, 2018-$159.12M–
FY2017Dec 31, 2017-$73.72M–
FY2016Dec 31, 2016-$84.39M–
FY2015Dec 31, 2015-$94.03M–
FY2014Dec 31, 2014-$51.45M–
FY2013Dec 31, 2013-$30.29M–
FY2012Dec 31, 2012-$15.51M–
FY2011Dec 31, 2011-$8.55M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.93M–
Q1 FY2026Mar 31, 2026-$22.73M–
Q4 FY2025Dec 31, 2025-$11.83M–
Q3 FY2025Sep 30, 2025-$5.86M–
Q2 FY2025Jun 30, 2025-$18.70M–
Q1 FY2025Mar 31, 2025-$38.98M–
Q4 FY2024Dec 31, 2024-$25.81M–
Q3 FY2024Sep 30, 2024-$19.45M–
Q2 FY2024Jun 30, 2024-$38.50M–
Q1 FY2024Mar 31, 2024-$43.73M–
Q4 FY2023Dec 31, 2023-$18.59M–
Q3 FY2023Sep 30, 2023-$29.53M–
Q2 FY2023Jun 30, 2023-$25.70M–
Q1 FY2023Mar 31, 2023-$18.91M–
Q4 FY2022Dec 31, 2022-$26.84M-205.4%
Q3 FY2022Sep 30, 2022-$28.37M–
Q2 FY2022Jun 30, 2022-$35.14M–
Q1 FY2022Mar 31, 2022-$59.20M–
Q4 FY2021Dec 31, 2021$25.48M–
Q3 FY2021Sep 30, 2021-$23.96M–
Q2 FY2021Jun 30, 2021-$55.75M–
Q1 FY2021Mar 31, 2021-$52.89M–
Q4 FY2020Dec 31, 2020-$30.63M–
Q3 FY2020Sep 30, 2020-$44.31M–
Q2 FY2020Jun 30, 2020-$40.28M–
Q1 FY2020Mar 31, 2020-$45.01M–
Q4 FY2019Dec 31, 2019-$39.49M–
Q3 FY2019Sep 30, 2019-$36.51M–
Q2 FY2019Jun 30, 2019-$48.20M–
Q1 FY2019Mar 31, 2019-$66.62M–
Q4 FY2018Dec 31, 2018-$48.17M–
Q3 FY2018Sep 30, 2018-$38.67M–
Q2 FY2018Jun 30, 2018-$37.63M–
Q1 FY2018Mar 31, 2018-$34.65M–
Q4 FY2017Dec 31, 2017-$5.54M–
Q3 FY2017Sep 30, 2017-$21.75M–
Q2 FY2017Jun 30, 2017-$21.72M–
Q1 FY2017Mar 31, 2017-$24.71M–
Q4 FY2016Dec 31, 2016-$20.00M–
Q3 FY2016Sep 30, 2016-$20.33M–

More Karyopharm Therapeutics figures

See a number that looks wrong?